Paulina Hill

About

Paulina Hill joined Sanofi Ventures in 2022 with a background in early stage biotech investing and company building. Her active investments include Attovia, Avilar, Latigo, Odyssey, NextPoint, Normunity, Nuvig, Tisento, Vrata and ZagBio. Prior investments include Aliada Therapeutics (acquired by Abbvie). Prior to joining Sanofi, Paulina was a Principal on the investment team at Omega Funds, where she incubated and served as the founding investor for Scorpion Therapeutics (acquired by Eli Lilly). Paulina’s investments also included Arrakis, IFM, Ikena (NASDAQ: IKNA), Synthekine, Theseus (NASDAQ: THRX), and Vanqua Bio. Paulina began her career with Polaris Partners. Paulina served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics (NASDAQ: CAMP), where she was the Founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at MIT. During her time at MIT, Paulina founded the MIT Postdoctoral Association and served as its President. Paulina also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team.